Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New hope for liver disease patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called CS0159 for people with primary biliary cholangitis (PBC), a chronic liver disease. It is for adults whose condition did not improve enough with or who cannot take the usual medicine, UDCA. About 135 participants will receive either CS0159 or a p…
Phase: PHASE3 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New pill could shrink fatty liver and help weight loss
Disease control Recruiting nowThis study tests an experimental medicine called CS060380, taken with a weight-loss drug (semaglutide), in adults with fatty liver disease (MASH) and obesity. About 120 people will join for up to 54 weeks. The goal is to see if the drug reduces liver fat and body weight safely.
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New pill aims to shrink fatty liver in 12 weeks
Disease control Recruiting nowThis study tests a new tablet, CS060380, for non-alcoholic steatohepatitis (NASH), a serious liver condition. About 120 adults will take the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track any side effects.
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 07, 2026 18:40 UTC